跳至主要内容
临床试验/NCT01776684
NCT01776684Unknown不适用

Detection of Resistance Genes From Serially Collected Plasma DNA in Non-small Cell Lung Cancer Patients Harboring EGFR Activating Mutation Who Are Being Treated With EGFR TKIs

Samsung Medical Center1 个研究点 分布在 1 个国家目标入组 200 人开始时间: 2012年6月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
不适用
入组人数
200
试验地点
1
主要终点
detection of resistant gene

研究概览

简要总结

To detect resistance gene from serially collected plasma DNA in non-small cell lung cancer harbouring EGFR activating mutation who are being treated with EGFR TKIs by using castPCR method.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
20 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Histologically confirmed NSCLC
  • Aged of or older than 20 years
  • ECOG performance status 0-2
  • Adequate hematological, renal, hepatic function
  • Patients with tumors harboring EGFR mutation (del 19 or L858R mutation)
  • Patient who are about to be treated with EGFR TKI (gefitinib, erlotinib or other EGFR TKI)
  • At least more than one measurable disease
  • Informed consent

排除标准

  • Active infection
  • Active bleeding

研究组 & 干预措施

EGFR positive arm

Experimental

Patients with NSCLC harboring activating EGFR mutation (deletion in exon 19, L858R mutation in exon 21)

干预措施: EGFR TKIs (gefitinib, erlotinib, afatinib, et al) (Drug)

结局指标

主要结局

detection of resistant gene

时间窗: 24 months

To evaluate the efficiency of castPCR method for detection of resistance genes, especially, T790M mutation from serially collected plasma DNA in non-small cell lung cancer patients harboring EGFR activating mutation who are being treated with EGFR TKIs

次要结局

未报告次要终点

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Myung-Ju Ahn

M.D., Professor

Samsung Medical Center

研究点 (1)

Loading locations...

相似试验